Home

This is an old revision of the document!


Aging and Olmesartan

with additional studies

Benefits of RAS blockade with olmesartan treatment are sustained after study discontinuation. 1)

In conclusion, there is no robust signal for harm with olmesartan use. 2)

Although uncontrolled confounding might still exist, olmesartan does not seem to increase cardiovascular risk compared with losartan. 3)

The ROADMAP study will answer the question whether an ARBA drug which is an angiotensin receptor blocker. One of the ARBs is olmesartan (Benicar). Not all ARBs activate the Vitamin D Receptor. can prevent or delay the onset of microalbuminuria and whether this translates into protection against cardiovascular events and renal disease. 4)

The data demonstrate potential benefits of reducing the heart rate of type 2 diabetes patients, and indicate that olmesartan could, in particular, reduce the risk of microalbuminuria in patients with low heart rate. 5)

Some of the documented protective effects of ARBs

include the ability to:

  • decrease the incidence and progression of Alzheimer's disease and dementia6)
  • prevent migraines7)
  • inhibit liver fibrosis and aid liver healing8)
  • reduce insulin resistance in rats9)
  • 6 mg/kg olmesartan reduces the inflammatory process and bone loss in rats10)
  • protect the mitochondria from age-associated damage from oxidation11)
  • play a protective role against proliferative diabetic retinopathy 12)
  • reduce liver fibrosis13)
  • treatment of anxiety and stress-related disorders14)
  • reduce oxidative damage15) and limit aging 16) 17)

Olmesartan and other ARBs have been used

to block various bad effects of Angiotensin II, including heart failure. In this regard, olmesartan has been shown to:

Dosage

80mg single dose vs 6hrlydosing
4 hourly compared to 6 hourly dosing

In August 2002, Trevor Marshall and Frances Marshall published a NetPrint about valsartan (Diovan), in which they reported that the once daily dosing of the ARB caused psychedelic dreams and psychotic events in two sarcoidosis patients. On the theory that these symptoms were caused by changes in plasma concentration, the frequency of the dosing of ARB was increased, which ended up reducing symptoms of disease including psychedelic dreams. This early insight into ARBs anti-inflammatory effects led Marshall to conclude that for an ARB to provide symptomatic relief, it was necessary to use more frequent dosing than typical. Professor Marshall would later go on to recommend frequent dosing of another ARB, olmesartan.

In rats, Olmesartan at 6 mg/kg optimally reduced the inflammatory process and bone loss27). That would be 9-10 tablets of Olmetec daily for a 64 Kg human

Olmesartan has also been shown to

  • prevent or delay left ventricular remodeling and hypertrophy in patients with type 2 diabetes 28)
  • reduce the volume of atherosclerotic plaques29) 30)
  • mildly reduce the risk of stroke in people at high risk for strokes (cerebrovascular events).31)
  • significantly remodel and destiffen the arterial wall material during long-term treatment 32)

A number of studies have found

that olmesartan and other ARBs possess various ways of protecting the kidneys from the effects of inflammation and cytokineAny of various protein molecules secreted by cells of the immune system that serve to regulate the immune system. damage:

  • in circadian rhythms between HR and MAP in CKD: Synchronization between the two rhythms was progressively lost as renal function deteriorated, and Olmesartan partly restored the synchronization 33)
  • in hypertensive patients with CKD, olmesartan add-on therapy improves the ambulatory BP profile via a preferential reduction in nighttime BP with concomitant renal injury inhibition 34)
  • results suggest olmesartan can help decrease plasma AGE levels in patients on HD 35)
  • renal protective effects of olmesartan may be better than those of other ARBs 36)
  • olmesartan may uniquely increase urinary ACE2 level, which could offer additional renoprotective effects 37)

Recent studies showed

  • treatment with olmesartan inhibited bone loss 38)
  • olmesartan protects endothelial cells against oxidative stress-mediated cellular injury 39)
  • decreases viability of malignant cell lines40)
  • carotid IMT and BP decreased similarly with olmesartan and atenolol; but only olmesartan reduced the volume of larger atherosclerotic plaques 41)
  • improvement of Plasma Biomarkers after switching stroke patients from other Angiotensin II Type I Receptor Blockers to Olmesartan 42)
  • improvement of glycemic control & insulin resistance was only observed in olmesartan group 43)
  • OLM substantially delayed the development of left ventricular remodeling in type 2 diabetes 44)
  • prevention of microalbuminuria in patients with type 2 diabetes and hypertension 45)

Long term treatment

Data suggest 40 & 80 mg olmesartan are able to significantly remodel & destiffen the arterial wall material during long-term treatment, partly independently of blood pressure, compared with 20 mg. hyper.ahajournals.org/content/early/2014/07/07/HYPERTENSIONAHA.114.03282.reprint 46)

1)
long:24772521
2)
long:24535009
3)
long:24516110
4)
long:16508590
5)
long:27082551
6)
long:20068258
7)
long:12503978
8)
long:12871826
9)
long:15127887
10) , 27)
long:23775504
11)
long:12709417
12)
long:17560613
13)
long:19303015
14)
long:15837532
15)
long:21504378
16)
long:19763608
17)
long:22283774
18)
long:16336207
19)
long:15879491
20)
long:15297251
21)
long:16939632
22)
long:16094406
23)
long:16534230
24)
long:27086671
25)
long:21881353
26)
long:24600204
28) , 44)
long:25275251
29) , 41)
long:19124398
30)
long:20202514
31)
long:19892999
32) , 46)
long:25001274
33)
long:23511341
34)
long:23154587
35)
long:22149003
36)
long:3862195
37)
long:24842388
38)
long:25363367
39)
long:25904217
40)
long:28666209
42)
long:25891757
43)
long:23303198
45)
long:22418908
home/food/aim_health/aging.1547164933.txt.gz · Last modified: 01.11.2019 by sallieq
© 2015, Autoimmunity Research Foundation. All Rights Reserved.